HIV encephalopathy presenting as schizophrenia-like delusions during highly active antiretroviral therapy (HAART) case report


After HAART (highly active antiretroviral therapy), which is a powerful antiviral drug regimen, was introduced into HIV therapy for AIDS patients, AIDS mortality decreased dramatically. The incidence of encephalopathy among AIDS patients was reported to be 10% to 40% in the past, but the introduction of HAART resulted in a decrease in HIV encephalopathy and an increase in mild CNS-related deficits, which affect the quality of life of AIDS patients. We report the case of an AIDS patient who developed schizophrenia-like delusions associated with encephalopathy. Administration of an antipsychotic drug and hypnotics was effective in relieving the symptoms of patients with insomnia, depressed mood, and delusions. Further information on the neuronal mechanism underlying the mental symptoms observed in our patient will be necessary to understand the process of pathogenesis of the encephalopathy and to devise an adequate clinical strategy for treatment.

Share and Cite:

Fuji, M. , Iseki, M. , Takeuchi, S. , Kakeda, K. , Shimodera, S. , Seo, H. and Inoue, S. (2011) HIV encephalopathy presenting as schizophrenia-like delusions during highly active antiretroviral therapy (HAART) case report. Open Journal of Psychiatry, 1, 132-136. doi: 10.4236/ojpsych.2011.13020.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Hashimoto, R., Mukai, E., Yokomaku,-Y., Mamiya, N. and Hamaguchi, M. (2008) Clinical features and courses of 5 cases with HIV encephalopathy. Clinical Neurology, 48, 173-178.
[2] World Health Organization. (2008) World health statistics, 13-14.
[3] Nakashima, Y., Inoue, M. and Isse, K. (2002) Psychiatric problems of AIDS and related disorder. Japanese Journal of Clinical Psychiatry, 31,925.
[4] Kopnisky, K.L. and Bao, J. (2007) HIV Preclinical therapeutics research: Central nervous system approaches. Journal of Neuroimmune Pharmacology, 2, 1.
[5] Bhaskaran, K., Mussini, C., Antinori, A., Walker, A. S., Dorrucci, M., Sabin, C., Phillips, A. and Porter, K. (2008) CASCADE collaboration. Change in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretrovairal therapy. Annals of Neurology, 63, 213-221. doi:10.1002/ana.21225
[6] Uehira, T. and Shirasaka, T. (2001) HIV-associated cognitive-motor complex/AIDS dementia complex. Clinic All-Round, 50, 2738.
[7] Simpson, D.M. (1999) Human immunodeficiency virus-associated dementia: Review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy. Clinical Infectious Disease, 29, 19-34. doi:10.1086/520150
[8] Bottiggi, K.A., Chang, J.J., Schmitt, F.A., Avison, M.J., Mootoor, Y., Nath, A. and Berger J.R. (2007) The HIV dementia scale: Predictive power in mild dementia and HAART. Journal of the Neurological Sciences, 260, 11-15. doi:10.1016/j.jns.2006.03.023
[9] Bandaru, V.V., McArthur, J.C., Sacktor, N., Cutler, R.G., Knapp, E.L., Mattson, M.P. and Haughey, N.J. (2007) Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology, 68, 1481-1487. doi:10.1212/01.wnl.0000260610.79853.47

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.